Evaluation of safety, effectiveness and duration of immunity after vaccination against Covid-19 in patients with autoimmune rheumatic diseases

• Conditions: autoimmune diseases; rheumatoid arthritis; systemic lupus erythematosus; Sjögren's syndrome; systemic scleroderma; myositis; vasculitis; spondylitis

• Registration Number: RBR-108fyykd
• Lead Sponsor: niversidade Federal de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-14
• Study Completion: 2021-10-03
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

rheumatoid arthritis; systemic lupus erythematosus; Sjogren's syndrome; systemic sclerosis; myopathies; vasculitis; spondyloarthritis; both sexes; age above eighteen years; medical indication to vaccinate against covid-19

Exclusion Criteria

Immunosuppressed by other causes; HIV; CD4 below two hundred cells; organ transplantation; primary immunodeficiency; cancer; myasthenia gravis; thymoma; absence or surgical removal of the thymus; pregnancy; history of severe adverse reaction to any vaccine previously administered

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the safety, effectiveness and duration of response to vaccines against Sars-Cov-2, in patients with immune-mediated Rheumatic Diseases, in the short and long term.

Secondary Outcome Measures

Name	Time	Method
To evaluate the effectiveness, duration and immunogenicity of the response to vaccines against Sars-Cov-2